On July 30, Veeva fell 5.1% in regular trading, trading at $198.01/share, with turnover of $79.58 million.

The decline was driven primarily by broad-based selling pressure across the Health Care Technology sector. Among peers, Teladoc Health plunged 27.72%, Waystar Holding dropped 16.15%, Doximity fell 5.09%, and Certara declined 2.35%, while VSee Health rose 6.43%.

On the company front, Veeva had recently received positive catalysts, including Guggenheim initiating coverage with a Buy rating on July 23, citing an average analyst price target of $241.04. The company's FY2027 Q1 earnings reported in early June were strong, with revenue of $882.9 million beating estimates and full-year adjusted EPS guidance raised to $9.05. Additionally, Veeva was added to the S&P 500 index in May. Despite these fundamental tailwinds, the stock was unable to resist sector-wide headwinds during the session.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)